Fundraising FoxActinium Pharmaceuticals, Inc.
New York, US
Find your way into Actinium Pharmaceuticals, Inc.
Sign up to see every warm intro you have to Actinium Pharmaceuticals, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Actinium Pharmaceuticals, Inc. team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Actinium is developing targeted radiotherapy treatments using Actinium-225 and related isotopes for oncology indications including prostate cancer, non-small cell lung cancer, breast cancer, and acute myeloid leukemia. The company's lead candidates include ATNM-400 for solid tumors and Actimab-A for blood malignancies.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 1 round · 2013
▶$6.6MraisedJan 2014 · 63 investors · PharmaceuticalsRule 506(b)
- Dragan CicicExecutive Officer
- David NicholsonDirector
- Sergio TraversaExecutive Officer, Director
- Kaushik J. DaveExecutive Officer, Director
- Sandesh SethDirector
- Richard I. SteinhartDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- Minimum investment
- $5K
- Sales commissions
- $663.7K
- Placement agents
- Recipient Laidlaw & Company (UK) Ltd.
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2023 | $865.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $378.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Actinium Pharmaceuticals, Inc. do?
- Actinium is developing targeted radiotherapy treatments using Actinium-225 and related isotopes for oncology indications including prostate cancer, non-small cell lung cancer, breast cancer, and acute myeloid leukemia. The company's lead candidates include ATNM-400 for solid tumors and Actimab-A for blood malignancies.
- How much funding has Actinium Pharmaceuticals, Inc. raised?
- Actinium Pharmaceuticals, Inc. has disclosed $6.6M raised across 1 round.
- Where is Actinium Pharmaceuticals, Inc. headquartered?
- Actinium Pharmaceuticals, Inc. is headquartered in New York, US.